Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du cancer

The LipSTIC LabEx consortium was created in 2012 and stands for Lipoproteins and health: prevention and Treatment of Inflammatory diseases and Cancer. The LipSTIC project is based on the disruptive concept that takes advantage of lipoprotein carrier properties to prevent, diagnose, treat and monitor non-vascular inflammatory diseases and cancer.

Since 2012, the LipSTIC has contributed to strengthen scientific originality and excellence at the interface of major research areas developed in the BFC region. It is organized in 5 working packages; 1)Transport and vectorization of bioactive molecules; 2)Lipids and inflammation in the initiation and progression of cancer, as well as in immunotherapy; 3)lipids and bacterial endotoxins in inflammatory diseases; 4)Scientific and therapeutic knowledge and innovations for health, 5)Valorization and regulation of innovative drugs.

The LipSTIC participates in the creation of new teaching programs: international Master’s degree dedicated to innovative strategies for imaging and nanovectorization and the graduate school INTHERAPI.

A major achievement is the transfer of knowledge to valorization with 22 patent registrations, 2 business units (Endoquant®, TASTE-EFFI®) and 2 startup creation (MED’INN Pharma®, EKTAH®). Transfer of knowledge to the public is a priority (cultural events, 4 children’s books) but also to the scientists and health professionals.

The LipSTIC has significantly boosts research impact, notably through funding leverage. For example, the licensing of a LipSTIC patent describing a biomarker associated with the risk to develop Age-Related Macular Degeneration, coupled with the establishment of an operational agreement with the startup RetiNov in 2022. Subsequently, the LipSTIC teams secured two additional sources of funding: €50k from INRAE to streamline and industrialize the biomarker assay, and €716k from the ANR BIOMAC to validate its prognostic value and identify the pathological thresholds across European cohorts.